Latest Breaking News On - Trastuzumab deruxtecan in combination with dna damage response pathway inhibitors - Page 1 : comparemela.com

Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.

Adrian gonzWashington university school of medicineWashington university schoolAdrian gonzálezWashington university school of medicine in st louisTrastuzumab deruxtecan in combination with dna damage response pathway inhibitorsHer2 low triple negative breast cancerTrastuzumab deruxtecan plus olaparib